<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101920</url>
  </required_header>
  <id_info>
    <org_study_id>20025408</org_study_id>
    <nct_id>NCT00101920</nct_id>
    <nct_alias>NCT00079209</nct_alias>
  </id_info>
  <brief_title>ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Clinical Trial of the Safety and Efficacy of ABX-EGF as Second Line Treatment for Advanced Non-Small Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in&#xD;
      kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor&#xD;
      prognosis. TGFa and EGF, the ligands for EGFR, are also overexpressed in some of these tumor&#xD;
      types, suggesting a self-propagating stimulus that may be responsible for rapid tumor growth.&#xD;
      Blocking this stimulus by blocking activation of EGFR with ABX-EGF, a fully human monoclonal&#xD;
      antibody against EGFR, may prevent tumor growth and perhaps shrink tumors. Purpose: This is a&#xD;
      Phase 2 clinical trial to evaluate the safety and efficacy of ABX-EGF in the treatment of&#xD;
      advanced NSCLC following failure of paclitaxel and carboplatin therapy on treatment arm 1 of&#xD;
      Immunex Protocol 054.0004 (Amgen Protocol 20025404), Part 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>End of initial 6 week treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ABX-EGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, single arm panitumamab monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX-EGF</intervention_name>
    <description>2.5 mg/kg by an infusion pump over one hour</description>
    <arm_group_label>ABX-EGF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Diagnosis of NSCLC.&#xD;
&#xD;
          -  Unidimensionally measurable disease.&#xD;
&#xD;
          -  Documented disease progression within 6 months of the subject's last dose of&#xD;
             carboplatin and paclitaxel in treatment arm 1, part 2 of Immunex Protocol 054.0004&#xD;
             (Amgen Protocol 20025404).&#xD;
&#xD;
          -  Disease stage IIIB with pericardial or pleural effusion, or stage IV.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  ANC greater than or equal to 1.5 x 10^9/L, platelet count greater than or equal to 100&#xD;
             x 10^9/L.&#xD;
&#xD;
          -  Adequate hematology function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  ECOG score of less than 2.&#xD;
&#xD;
          -  Brain metastases, if present, must be controlled and asymptomatic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Calcium &gt;ULN (treatment for hypercalcemia allowed).&#xD;
&#xD;
          -  Use of any investigational therapy within 30 days of ABX-EGF infusion.&#xD;
&#xD;
          -  Any cancer therapy for NSCLC other than paclitaxel and carboplatin per Immunex&#xD;
             Protocol 054.0004 (Amgen Protocol 20025404), such as radiation therapy, surgery, or&#xD;
             steroids.&#xD;
&#xD;
          -  Paclitaxel or carboplatin within 30 days before the first ABX-EGF infusion.&#xD;
&#xD;
          -  Radiation therapy within 2 weeks before ABX-EGF infusion.&#xD;
&#xD;
          -  LVEF less than 45% as measured by MUGA.&#xD;
&#xD;
          -  Symptomatic ventricular arrhythmia or symptomatic conduction abnormality.&#xD;
&#xD;
          -  Myocardial infarction within 1 year before first dose of study drug.&#xD;
&#xD;
          -  History of cancer that has required treatment or been active within past 5 years,&#xD;
             other than NSCLC, basal cell carcinoma, or cervical carcinoma in situ.&#xD;
&#xD;
          -  Women (e.g., of childbearing potential, who are post-menopausal for less than six&#xD;
             months, not surgically sterilized or not abstinent) who are not willing to use an oral&#xD;
             or implanted contraceptive, double barrier birth control, or an IUD during the course&#xD;
             of the study and for 6 months following treatment.&#xD;
&#xD;
          -  Men not willing to use contraception upon enrollment into this study and for 1 month&#xD;
             following treatment.&#xD;
&#xD;
          -  Women who are breast-feeding or have a positive pregnancy test within 72 hours of&#xD;
             first study drug administration.&#xD;
&#xD;
          -  Known to be HIV positive.&#xD;
&#xD;
          -  Any patient who's best medical interests would not be met by entry in the study in the&#xD;
             opinion of the Investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>January 18, 2005</study_first_submitted>
  <study_first_submitted_qc>January 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2005</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

